预后评估与管理路径缩短急性肺栓塞住院时间的随机对照试验
本研究为随机对照试验,纳入500例急性肺栓塞住院成人,评估以预后评估与管理路径(风险分层后按预设标准活动和出院)对比常规诊疗对住院时间的影响。结果显示干预组中位住院时间4.0天,对照组6.1天(p<0.001),且干预组预后检查费用和住院总费用均更低,30天再入院率、全因死亡率和肺栓塞相关死亡率无显著差异。
要点
- 预后评估与管理路径可显著缩短急性肺栓塞患者住院时间。
- 干预组预后检查费用和住院总费用均低于常规诊疗组。
- 30天再入院率、全因死亡率和肺栓塞相关死亡率无显著差异。
核心结论
- 对急性肺栓塞住院患者采用预后评估与管理路径可有效缩短住院时间。
研究设计与样本
- 随机对照试验,500例急性肺栓塞住院成人随机分组,498例纳入改良意向性分析。
- 干预组采用包含风险分层及预设活动和出院标准的预后评估与管理路径,对照组为常规诊疗。
主要发现
- 干预组中位住院时间4.0天(IQR 3.7-4.2天),对照组6.1天(IQR 5.7-6.5天),p<0.001。
- 干预组预后检查平均总费用174.76欧元,对照组233.12欧元,平均差-58.37欧元(95%CI -84.34至-32.40)。
- 干预组每例患者平均住院总费用2085.66欧元,对照组3232.97欧元,平均差-1147.31欧元(95%CI -1414.97至-879.65)。
- 30天再入院率4.0% vs 4.8%,全因死亡率2.4% vs 2.0%,肺栓塞相关死亡率0.8% vs 1.2%,均无显著差异。
关键数值与推荐
- 干预路径包含风险分层后按预设标准进行活动和出院。
- 主要终点为住院时间,次要终点为预后检查费用、住院费用及30天临床结局。
临床怎么用
- 对急性肺栓塞住院患者可考虑采用预后评估与管理路径以缩短住院时间并降低费用。
- 该路径未增加30天再入院率、全因死亡率或肺栓塞相关死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The length of hospital stay (LOS) for acute pulmonary embolism (PE) varies considerably. Whether the upfront use of a PE prognostic assessment and management pathway is effective in reducing the LOS remains unknown. METHODS: We conducted a randomised controlled trial of adults hospitalised for acute PE: patients were assigned either to a prognostic assessment and management pathway involving risk stratification followed by predefined criteria for mobilisation and discharge (intervention group) or to usual care (control group). The primary end-point was LOS. The secondary end-points were the cost of prognostic tests and of hospitalisation, and 30-day clinical outcomes. RESULTS: Of 500 patients who underwent randomisation, 498 were included in the modified intention-to-treat analysis. The median LOS was 4.0 days (interquartile range (IQR) 3.7-4.2 days) in the intervention group and 6.1 days (IQR 5.7-6.5 days) in the control group (p<0.001). The mean total cost of prognostic tests was EUR 174.76 in the intervention group, compared with EUR 233.12 in the control group (mean difference EUR -58.37, 95% CI EUR -84.34- to -32.40). The mean total hospitalisation cost per patient was EUR 2085.66 in the intervention group, compared with EUR 3232.97 in the control group (mean difference EUR -1147.31, 95% CI EUR -1414.97- to -879.65). No significant differences were observed in 30-day readmission (4.0% versus 4.8%), all-cause mortality (2.4% versus 2.0%) or PE-related mortality (0.8% versus 1.2%) rates. CONCLUSIONS: The use of a prognostic assessment and management pathway was effective in reducing the LOS for acute PE.
引用
- Jiménez D, Rodríguez C, León F, et al. Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. Eur Respir J. 2022. PMID: 34385269. doi:10.1183/13993003.00412-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。